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Background: In fish breeding, it is essential to discover and generate fish exhibiting an effective phenotype for the
aquaculture industry, but screening for natural mutants by only depending on natural spontaneous mutations is
limited. Presently, reverse genetics has become an important tool to generate mutants, which exhibit the
phenotype caused by inactivation of a gene. TILLING (Targeting Induced Local Lesions IN Genomes) is a reverse
genetics strategy that combines random chemical mutagenesis with high-throughput discovery technologies for
screening the induced mutations in target genes. Although the chemical mutagenesis has been used widely in a
variety of model species and also genetic breeding of microorganisms and crops, the application of the
mutagenesis in fish breeding has been only rarely reported.
Results: In this study, we developed the TILLING method in fugu with ENU mutagenesis and high-resolution
melting (HRM) analysis to detect base pair changes in target sequences. Fugu males were treated 3 times at weekly
intervals with various ENU concentrations, and then the collected sperm after the treatment was used to fertilize
normal female for generating the mutagenized population (F1). The fertilization and the hatching ratios were similar
to those of the control and did not reveal a dose dependency of ENU. Genomic DNA from the harvested F1
offspring was used for the HRM analysis. To obtain a fish exhibiting a useful phenotype (e.g. high meat production
and rapid growth), fugu myostatin (Mstn) gene was examined as a target gene, because it has been clarified that
the mstn deficient medaka exhibited double-muscle phenotype in common with MSTN knockout mice and bovine
MSTN mutant. As a result, ten types of ENU-induced mutations were identified including a nonsense mutation in
the investigated region with HRM analysis. In addition, the average mutation frequency in fugu Mstn gene was 1
mutant per 297 kb, which is similar to values calculated for zebrafish and medaka TILLING libraries.
Conclusions: These results demonstrate that the TILLING method in fugu was established. We anticipate that this
TILLING approach can be used to generate a wide range of mutant alleles, and be applicable to many farmed fish
that can be chemically mutagenized.
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Mutations are the basis of genetic variation and mutant
populations are indispensable genetic resources in all organ-
isms. This variation can be either naturally occurring or, in
plants, animals and lower organisms, induced by chemical
or physical treatments. Mutation induction, for example,
has played an important role in the genetic improvement of
crop species that are of economic significance.
In breeding of aquacultural fish species, it is a final
goal to discover and generate the fish with various useful
phenotypes for supplying to consumers. Currently gen-
etic breeding is carried out with the search for natural
variation in traits such as growth, productivity and dis-
ease resistance, and then improved strains are produced
by genetic selection or marker-assisted breeding ap-
proaches [1]. Thus the success of fish breeding solely de-
pends on the mutations pre-existing in the focal
population. The rate of natural spontaneous mutations
in fish species is generally lower than 1.0×10-6 at specific
loci. On the other hand, mutation frequency caused by
radiation and chemical mutagenesis range from 1.0×10-3
to 3.9×10-3 at specific loci when in vivo spermatogonial
treatments were carried out in zebrafish and medaka
[2-4]. Given the high frequency of the mutation ratio, it
is reasonable to consider that the chemical mutagenesis
will be an efficient way to produce new mutants for fu-
ture genetic improvement in aquacultural species.
TILLING (Targeting Induced Local Lesions IN Ge-
nomes) is a reverse genetics strategy that identifies in-
duced mutations in specific genes of interest in chemically
mutagenized populations with high-throughput discovery
technologies. TILLING, first described in 2000 for muta-
tion detection in Arabidopsis [5], is now used in a wide
range of plants including soybean [6], rice [7], barley [8]
and maize [9] as well as for animal model systems, includ-
ing Drosophila [10], Caenorhabditis elegans [11], rat [12],
medaka [13], zebrafish [14] and for the discovery of natur-
ally occurring polymorphisms in humans [15].
The first step in TILLING is chemical mutagenesis. In
plants, mutations have been induced by using ethyl-
methane sulfonate (EMS) and methylnitrosourea (MNU)
[5,7]. In animals, EMS is used in many invertebrate spe-
cies for mutagenesis, whereas N-ethyl-N-nitrosourea
(ENU) is used for males of vertebrates, and is the most
widely employed method [16]. ENU acts as an alkylating
agent and transfers its ethyl group to nucleophilic nitro-
gen or oxygen sites on deoxyribonucleotides, leading to
base mismatch during DNA replication. Single-base sub-
stitutions that resemble natural spontaneous mutations
[17,18], are mainly induced by ENU treatment and all
genes are mutated at random [19]. Because this protocol
induces mutations in germ-line stem cells, mutations are
transmitted at the rate for at least several months after
the treatment. Also, the mutations are induced withpremeiotic ENU treatment, so that the initial mutation,
usually an ethylation of a base on one DNA strand, is
fixed by DNA replication prior to production of differen-
tiated sperm, leading to non-mosaic offspring in the next
generation [16]. On the other hand, it has been recently
reported that some point mutations were induced by
postmeiotic mutagenesis in Ctenopharyngodon idellus
(grass carp) with ENU for mature sperm [20]. In zebra-
fish, the postmeiotic ENU mutagenesis resulted in mo-
saic progeny, but produced a 10 fold increase in the
frequency of induced mutations [21]. This protocol in
zebrafish has been also shown to induce mutations such
as deletions and translocations triggered by chromo-
somal rearrangements [18]. These results indicate that
postmeitotic ENU treatment of male germ cells can in-
duce a variety of mutations from point mutations to de-
letions and translocations.
In zebrafish and medaka, which are model fish, muta-
tions are introduced in spermatogonia by soaking founder
fish in ENU solution [13,22]. However, this protocol is dif-
ficult to apply to many aquaculture species including fugu,
as the body size of these fish is markedly larger than that
of medaka and zebrafish. Thus alternative protocols are
required for fish with a large body size.
After the ENU treatment, a large F1 population is gen-
erated to choose the mutations for purpose from many
random heterozygous mutations in their genomes. As
the next step in TILLING, the genomic DNA from these
animals containing induced mutations is screened with
discovery technologies. Sequencing is considered the
standard for DNA-based mutation detection because it
reveals the exact location and the type of mutations.
Taniguchi et al. employed a direct sequencing approach
even for the prescreening step [13]. CEL I nuclease-
mediated screening of heteroduplexes are widely carried
out to detect mutations in TILLING [23,24]. Both
methods are effective, but the costs are substantial and it
takes a relatively long time for the screening. Recently,
high resolution melting (HRM) analysis has succeeded
to detect point mutations in plant populations [25], me-
daka TILLING library [26] and human disease [27].
HRM analysis makes use of characteristics in DNA as
follows; the thermal stability of a DNA fragment is de-
termined by its base sequence. When the DNA fragment
contains an altered sequence, the duplex stability is
changed, leading to different melting behavior. Thus
changes in the sequence within the DNA fragment such
as point mutation can be detected by the melting
analysis.
To apply TILLING technology for breeding practices,
it is critical to select a proper target gene in which muta-
tions are likely to cause useful phenotypes such as rapid
growth and disease resistance. One of the growth-related
factors, Myostatin (Mstn) is a member of the transforming
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negative regulator of skeletal muscle mass [28]. Naturally
occurring mutations in the Mstn gene have been identified
in double-muscling cattle breeds [29,30], mice [28], dogs
[31] and even humans [32]. Recently, we have demon-
strated that the antagonistic role of Mstn against muscle
growth is conserved from mammals to fish species [33].
Indeed mstn-deficient medaka (mstnC315Y), which were
generated by the TILLING method, show a significant in-
crease in body weight in comparison with wild-type me-
daka, due to over-growth of muscles. Therefore, Mstn is a
promising target gene for mutation breeding in fishes.
Here, in order to initiate targeted mutation breeding
in fish improvement, we searched for efficient methods
for TILLING combining ENU mutagenesis with HRM
analysis in Takifugu rubripes, tiger pufferfish (fugu).
Fugu males were treated with ENU via intraperitoneal
injection each week for three weeks, and the sperm col-
lected from the founder fish was used for in vitro
fertilization to obtain the progeny. We then isolated gen-
omic DNA from the progeny, and carried out HRM ana-
lysis targeting the exon 3 of fugu Mstn gene. Our
screening successfully identified ten mutations including
one nonsense mutation in fugu Mstn gene. The muta-
tion frequency in fugu Mstn gene was similar to that
identified in the medaka TILLING library, demonstrating
that we were able to establish an effective protocol of
the TILLING method in fugu. This protocol is likely to
be applicable to various species of aquacultured fish.
Results
Development of the ENU mutagenesis protocol for fugu
TILLING
In order to develop a protocol for ENU mutagenesis in
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Figure 1 Scheme design of the ENU mutagenesis in fugu. A) The num
injections was examined. ENU (concentration: 70 mg/kg body weight of fu
fugu males at the stage before spermiation. B) Treatment with various ENU
and sperm collection. Founder fish were treated with three ENU concentra
spermiation. As a control, the fish were treated with buffer (0 mg/kg body
intramuscularly at 2 or 3 weeks after the last ENU injection. Sperm was collreferring to the method used for mouse mutagenesis
[34]. Previous study has shown that inheritable point
mutations are induced by ENU treatment at the sperm-
atogonia stage in mouse [35]. Based on the report, fugu
males were injected with ENU at a dose of 70 mg/kg
body weight, 3 times at weekly intervals at the stage be-
fore spermiation when early stages of spermatogenesis
were progressing (Figure 1A). The injected fish began to
die at 4 to 6 weeks after the last ENU treatment (average
survival rate: 71%). The surviving fish were treated with
the hormone, gonadotropin, to trigger sperm production
and spermiation. Their sperm was collected for
fertilization and cryopreservation during 6 to 7 weeks
after the ENU treatment. No fish survived more than
9 weeks after the last ENU treatment. We then per-
formed in vitro fertilization using the collected sperm to
obtain mutagenized F1 fry. The average fertilization ratio
was 89%, which is comparable to the ratio of non-
mutagenized sperm. Although the hatching ratio was
low (average: 23%), most of the hatched fry had a normal
appearance without teratogenesis. Therefore, we deter-
mined the method for the ENU mutagenesis in fugu as
follows: the founder fish are treated with the 70 mg/kg
of ENU concentration 3 times at weekly intervals during
the early mature stage to the late maturation stage in
spermatogenesis of the fish.
ENU treatment in TILLING method has been shown
to effectively produce a lot of mutations. In mouse, ENU
induces mutations at a relatively high rate with a dose
dependency [36]. Next, we examined whether various
ENU concentrations were effective on viability of the
founder fish and their progeny (Figure 1B). The fish
were injected intraperitoneally with ENU at a dose of 7,
70 or 120 mg/kg body weight, and with the buffer pre-
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ber of ENU treatments in fugu. The number and timing of ENU
gu) was injected 3 times at weekly intervals into the intraperitoneal of
concentrations, and timing of gonadotrophin (HCG/SPH) treatment
tions (7, 70, 120 mg/kg body weight of fugu) at the stage before
weight of fugu) instead of ENU. HCG/SPH was injected into the fugu
ected at 3, 5, and 6 weeks after the last ENU injection.
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examined the number of surviving founder fish after
treatment with each ENU concentration. Although al-
most all fish with ENU in a dose of 7, 70 mg/kg (survival
rates: 100% and 92%, respectively) survived at 4 weeks
after the last ENU treatment, the fish with ENU in a
dose of 120 mg/kg (survival rate: 67%) began to die at
that time. The fish, which were collected sperm at
8 weeks after the last ENU treatment, survived till
5 months after the ENU experiments. Final survival rates
of each ENU concentration were as follows: 7 mg/kg,
100%; 70 mg/kg, 50%; 120 mg/kg, 33%. After gonado-
tropin treatment in each family, the collected sperm was
used for in vitro fertilization. The fertilization ratio
(average: 72%) and the hatching ratio (average: 54%) in
each cross were similar to those of control (67% and
53%, respectively; Table 1). More than ten thousand
hatched fry of fugu were obtained in each family. They
revealed that the fertilization and hatching ratios were
unaffected by the dosage of ENU when the concentra-
tion of ENU was varied from 7 mg/kg to 120 mg/kg.
In the course of the above experiment, we noted that
the ENU-treated founder fish did not spermiate without
the gonadotropin treatment injection. Then, we investi-
gated the timing of the gonadotropin treatment to
maximize the amount of sperm to collect (Figure 1B).
Gonadotropin treatment was performed with the fish at
2 or 3 weeks after the last ENU treatment, which was
the stage before the fish began to die as described above.
To determine the time period for sperm collection after
the gonadotropin treatment, we counted the number of
spermiated fish at 3, 5 and 6 weeks after the last ENU
treatment, and measured the volume of sperm (Table 2).
In the gonadotropin treatment at 2 and 3 weeks after
the last ENU treatment, sperm was collected at both 5
and 6 weeks, while fish did not spermiate at 3 weeks
after the last ENU treatment. The frequency of sper-
miated fish was higher in the gonadotropin treatment atTable 1 Effects of various ENU concentrations on













In vitro fertilization was carried out by using eggs from wild-type fugu and the
sperm treated with ENU concentrations as described above. 100 of fertilized
eggs in each family were counted at the 4 cell stage for fertilization ratio,
while at the melanophore appearing stage for the hatching ratio. These ratios
were calculated according to Methods. Founder fish treated with buffer was
used as the control (ENU conc., 0 mg/kg).3 weeks than at 2 weeks after the last ENU treatment.
There was no noticeable difference between the volume
of sperm in each week after the gonadotropin treatment.
In the control without the gonadotropin treatment, the
fish did not spermiate until 5 weeks after the last ENU
treatment, and produce a very small amount of sperm at
6 weeks. The volumes of all sperm collected under these
conditions were sufficient for cryopreservation, except
for the fish without hormonal treatment. From the re-
sults, we fixed the method as follows: the gonadotropin
treatment for the founder was carried out at 3 weeks
after the last ENU treatment, and then the sperm from
the fish was collected at 3 weeks after the gonadotropin
treatment.
Target gene for generation of a fugu mutant with TILLING
Our long-term goal is to generate a fugu line that exhibits a
useful phenotype for the aquaculture industry by TILLING
and to apply this technology to a variety of aquacultured
species. Recently, we have reported that myostatin (mstn)-
deficient medaka exhibited a double-muscling phenotype
with hyperplasia and hypertrophy [33]. There is a high pos-
sibility that Mstn-deficient fugu exhibits such the pheno-
type, if a mutation is found in the same position or the
significant region of mstn gene in medaka. Therefore, we
amplified presumable full-length cDNA of fugu Mstn using
cDNA from the muscle as a template. Sequencing of these
products indicated that fugu Mstn comprises 3 exons, and
encodes a protein consisting of 375 amino acids (Figure 2A).
The fugu Mstn amino acid sequence has 83.8% identity to
medaka and highly 88.1% identity in the C-terminal active
peptide of Mstn (Figure 2B). Search in the fugu genome as-
sembly suggested that fugu has a single copy of this gene.
Detection of ENU-induced mutations in fugu with HRM
analysis and DNA sequencing
Since TILLING can identify mutations in the heterozy-
gous condition, it is possible to screen using the F1 off-
spring of ENU mutagenesis. We performed the HRM
analysis to screen for ENU-induced mutations in the C-
terminal region of fugu Mstn gene, since the region is
highly conserved among vertebrates (Figure 2), and is re-
sponsible for the function of Mstn [37]. To screen cor-
rectly and quickly a large amount of genomic DNA,
efficient protocols for HRM analysis were explored with
a DNA automatic dispensing machine and a detection
device for 384 samples. Genomic DNA was extracted
from 1,056 fry obtained from in vitro fertilization with
the ENU-treated sperm. These DNA were subjected to
the nested PCR with some primers of the fugu Mstn
(see Methods) and two amplicons Figure 2A (268 bp
and 281 bp) were used for HRM analysis. Examples of
the melting curves and the differentiation plots in fugu
Mstn gene are shown in Figure 3. The mutation
Table 2 Effects of gonadotropin treatment on timing of sperm collection and the sperm volume in fugu
Period after the last ENU treatment

























Gonadotropin treatment (2 weeks
after the last ENU treatment)
70 0/4 (0) 0 2/4 (50) 5-15 3/4 (75) 4-10
Gonadotropin treatment (3 weeks
after the last ENU treatment)
0 - - 2/2 (100) 4-9 1/1 (100) 6
7 - - 3/3 (100) 7.5-30 3/3 (100) 8-10
70 - - 3/3 (100) 10-17.5 3/3 (100) 5-7
120 - - 0/2 (0) 0 1/1 (100) 3
Non-gonadotropin treatment (control) 70 0/3 (0) 0 0 3/3 (100) 0.2-2
(%)* reveals ratio of fish which were able to collect the ENU-mutagenized sperm to the examined fish.
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red lines). The amplicons selected as positive samples
were subjected to direct sequencing in order to confirm
whether they contain mutations. Overlapping peaks in
the DNA sequence traces revealed that an F1 individual
carries a heterozygous point mutation (Figure 4), whileFigure 2 Fugu Mstn profiles. A) Genome structure of fugu Mstn gene (1
number of exons) and bars, introns. B) Sequence alignment of fugu [GenB
[GenBank, NP_001001525] Mstn protein. Amino acids conserved across the
Mstn shows 83.8% and 60.1% identity to that of medaka and bovine, respe
for the function, is outlined in light blue. The underlined cysteines are esse
has an 88.1% identity to medaka and bovine Mstn. Black triangle, the amin
bovine. Bidirectional bold and thin arrows (A) and bold characters (B), thethis mutation was not observed in the rest of the siblings
as well as in both parents. The results demonstrate that
the mutations were induced by ENU treatment in fugu.
As shown in Table 3, ten types of mutations were de-
tected by HRM analysis and then confirmed by direct
sequencing (nonsense, 1; missense, 7; silent, 2). Also, it905 bp). Black boxes, exons (with the Roman numeral representing the
ank, ADT89782], medaka [GenBank, NP_001188428] and bovine
three species are outlined in red. The amino-acid sequence of fugu
ctively. The C-terminal peptide, which is considered to be significant
ntial for the activity of Mstn in vertebrate. The fugu C-terminal region
o acid responsible for the loss-of-function phenotype in medaka and
region examined by the HRM analysis in this study.
Figure 3 ENU-induced mutations in fugu Mstn gene detected by HRM analysis. The exon 3 of the Mstn gene was examined by HRM
analysis with each family of fugu genomic DNA. The region contains the C-terminal peptide of the fugu Mstn protein. The family numbers mean
the line of the hatched fry generated by in vitro fertilization (see Table 3). Left side of figures, the high-resolution melting curve (A, C, E, G), and
right side of the figures, the substitution plots (B, D, F, H). X-axis and Y-axis, temperature (°C) and relative signal difference, respectively. Red lines
and black arrows, the mutations screened by the HRM analysis.
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were point mutations. The number of the induced muta-
tions was an average of 1 to 2 in each family treated with
various ENU concentrations (7, 70, 120 mg/kg body
weight). When the effect of injection into fugu on the
mutations was examined in the control (0 mg/kg body
weight), no mutations were recognized. This indicates
that the number of induced mutations does not depend
on the concentration of ENU within the range of 7 to
120 mg/kg. Consistent with this, the dose-dependent ef-
fects were not observed on the fertilization and the
hatching ratios (Table 2).
Identification of Mstn-deficient mutation in fugu
The nonsense mutation we discovered changes a cyto-
sine to an adenine in exon 3 of fugu Mstn converting a
tyrosine codon to a stop codon in a fry from the family
4 (Figure 5A, B, Table 3). While the fry was heterozygous
at this site, its parents and control fish were homozygous
(Figure 5B), suggesting that the mutation was inducedby the ENU treatment. DNA sequencing of the amplicon
cloned into a plasmid vector confirmed the presence of
this mutation (Figure 5C). The nonsense mutation was
also examined with CEL I assay (Figure 5D). The cleav-
age product was detected in the CEL I reactions of the
mutant DNA (lane 6), but they were not in the reactions
of wild-type DNA (lanes 1–5). The mutation likely re-
sults in the loss-of-function of Mstn in fugu, as a critical
part of the amino acid chain, the C-terminal peptide, are
no longer created due to the stop codon.ENU-induced mutation ratio in fugu
The mutation ratio in the mutagenesis is a key point to
produce the mutants effectively. Therefore, the ratio was
calculated using data detected in fugu Mstn gene by
HRM analysis. We screened about 3.0 Mb in total and
identified 10 independent mutations (Table 3). There-
fore, the ENU-induced mutation ratio for fugu Mstn
gene was one substitution per 297 kb.
Figure 4 ENU-induced point mutations in fugu Mstn gene identified by direct sequencing. The PCR products from fugu genomic DNA
screened by the HRM analysis were investigated by direct sequencing. Left side (A, C, E, G) and right side (B, D, F, H) of figures, the sequence traces
of wild-type fugu (WT) and the fugu mutant (F1). Lines in green, red, black and blue; adenine, thymine, guanine and cytosine, respectively. A nucleotide
in the germ cell in the founder fish (black triangles) is replaced by another nucleotide due to the ENU-treatment (red triangles), resulting in an offspring
that is heterozygous at the site. The numbers mean the line of the hatched fry generated by in vitro fertilization (see Table 3).










1 7 CTGGGACTGG(A > G)CTGCGACGAG D272G
1 7 TTGCAGAAAT(A > G)CCCGCACACC Y322C
2 70 gCAACCTTTC(A > G)TGGAGGTGAA M254V
3 70 GAGACCTGGG(A > G)CTGGACTGCG G270G
3 70 CACCTGGTGA(A > G)CAAGGCCAAC N329S
4 70 AGTGTGAGTA(C > A)ATGCACTTGC Y316X
5 70 CGCACACCCA(C > T)CTGGTGAACA H326H
5 70 AGGGACCGCG(G > A)GCCCTTGCTG G338S
6 120 CATGCTCTAC(T > C)TCAACCAAGA F354L
6 120 CTCTACTTCA(A > G)CCAAGAACAG N355S
(A > B): A is the nucleotide of wild-type and B is the nucleotide of the mutant.
X indicates a stop codon. There were ten types of mutation in the investigated
region with HRM analysis (nonsense, 1; missense, 7; silent, 2). The nonsense
mutation is underlined.
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Establishment of fugu TILLING
Schematic model for fugu TILLING method is summa-
rized in Figure 6 as follows: fugu males are treated with
ENU 3 times at weekly intervals at the stage before sper-
miation and then treated with gonadotropin at 3 weeks
after the last ENU treatment to facilitate the sperm pro-
duction and spermiation. The sperm from the founder
fish was collected at 3 weeks after the gonadotropin
treatment and used for in vitro fertilization to obtain
hatched fry. The genomic DNA extracted from the fry
was subjected to PCR and the amplicons were used to
screen ENU-induced mutations with HRM in a fugu
gene of interest. Our study firstly demonstrated that
TILLING technology is applicable to aquacultured fish.
Interestingly, the TILLING approach in fugu could be
used in a similar way as in plants [38]. We can treat
them like plant seeds derived from mutagenized ances-
tor, because sufficient eggs and sperm to obtain a large
amount of F1 progeny are prepared for a single pair of
fugu female and male. Furthermore, mutations induced
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Figure 5 Identification of the ENU-induced nonsense mutation in fugu TILLING. A) The high-resolution melting curve (left) and the substitution
plot (right). Exon 3 of the Mstn gene, which contains the C-terminal region of the Mstn protein, was examined by HRM analysis using the fugu family 4 (see
Table 3). Red curve, the deviated curve due to mutation. B) Direct sequencing for the selected mutations. The selected genomic DNA with the HRM analysis
was investigated by direct sequencing. Lines in green, red, black and blue; adenine, thymine, guanine and cytosine, respectively. The sequence traces of the
fugu parents (Founder-♂ and -♀), control (Control), and the ENU-induced mutant (F1) are illustrated in order from left to right. Cytosine in the parents (black
triangles) is substituted to adenine in the mutant (red triangle), resulting in the change from tyrosine to a stop codon at amino acid 316. C, D) Confirmation of
the nonsense mutation in fugu TILLING. PCR amplicons were cloned and sequenced to confirm the substitution of the nucleotide (C). The sequence traces of
the cloned wild-type and the mutant DNA are illustrated in left (WT) and right (mutation), respectively. Cytosine to adenine nucleotide transition was recognized.
The cleavage product was detected with CEL I assay in the mutant DNA (D, lane 6), but not in wild-type DNA (D, lanes 1–5). Black arrow, the cleavage product.
E) Nonsense mutation in the C-terminal region of fugu Mstn. The ENU-induced point mutation in fugu TILLING caused the substitution to a stop codon in the
C-terminal region. Bold characteristics, six cysteines which are essential for the Mstn conformation. X, a stop codon. Black and white triangles, amino-acid change
from tyrosine to a stop codon in fugu Mstn; the change from cysteine to tyrosine in medaka Mstn responsible for the phenotype, respectively.
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Figure 6 Establishment for the fugu TILLING method. Mutagenesis was carried out with injection of ENU (conc., 70 mg/kg body weight) into
founder fugu 3 times at weekly intervals. Half of the founder fish died around 6 weeks after the last ENU treatment. Sperm was not obtained
from the founder until 5 weeks after the last ENU treatment. To collect the sperm from the founder, gonadotrophin (HCG/SPH) was injected once
3 weeks after the last ENU treatment. The sperm was collected 3 weeks after the hormone treatment and then cryopreserved for a long-term
TILLING resource. For screening strategy, the hatched fry were obtained in vitro fertilization with the collected sperm and eggs from wild-type
female. Genomic DNA extracted from the fry was used to screen the induced mutations in Mstn gene with HRM analysis. The screened mutations
were confirmed by direct sequencing and CEL I assay. These approaches demonstrate that the TILLING method was established in fugu.
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used for the cross. On the contrary, it has been pointed
out that non-predictable frequency of endogenous SNP
in a mutagenized bank derived from multiple founders is
an obstacle for the screening in zebrafish and medaka
[13,22]. TILLING can be considered as an appropriate
method for many aquacultured fish producing a large
number of eggs.
Recently, in vitro ENU mutagenesis of postmeiotic
sperm was performed in grass carp [20]. In their study,
the induced mutations were investigated using growth-
related genes (Igf-2a, Igf-2b, Mstn-1, Mstn-2, Fst-1 and
Fst-2) and the estimated mutation ratio was around
0.41%. However, the mutations are apparently mosaic in
F1 individuals. Mosaicism of the induced mutation was
also reported in zebrafish when postmeiotic sperm was
mutagenized [21]. This situation makes recovery of the
mutant line inefficient in contrast to the case of non-
mosaic mutation induced by ENU-treatment of spermato-
gonia [21]. The mosaicism in F1 individuals and resulting
non-Mendelian transmission from F1 to F2 generations
hinder some screening protocols. In addition, large-scale
rearrangements of the genomic structure such as trans-
location of genomic segments have been reported follow-
ing the mutagenesis of postmeiotic sperm [18]. Therefore,
the suitability of the in vitro ENU mutagenesis of post-
meiotic sperm for mutation breeding in fish improvement
remains to be verified. Although the in vitro ENUtreatment is more convenient than the in vivo methods
used in fugu and other model animals, it will be required
to examine whether the induced mutations will be inher-
ited by the progeny in the mutants.
In TILLING, high efficiency for ENU-induced muta-
tions is required to obtain various phenotypes in gene of
interest. A previous report indicated that the induced
mutation frequency increased with ENU dose depend-
ently in mouse [36]. In this study, there was no differ-
ence in the number of surviving fish, fertilization and
hatching ratios in ENU treatment with 7, 70 mg/kg
(Table 2). ENU treatment with 120 mg/kg affected
slightly on the number of surviving treated fugu. How-
ever, the number of the induced mutations did not tend
to increase in each ENU concentration between 7 mg/kg
and 120 mg/kg (Table 3). These results suggested that
each ENU concentration in the method may become sat-
uration in premeiotic sperm (spermatogonia and sperm-
atocyte cells) of fugu.
Identification of fugu Mstn mutant
It has been reported that loss of the Mstn function in
medaka and mice causes double-muscling phenotype
with both hyperplasia and hypertrophy [28,33]. In the
present study, ENU-induced mutations in fugu Mstn
were confirmed and in particular, the nonsense mutation
(Y316X) was identified at C-terminal region of the pep-
tide. The mstn mutant medaka (mstnC315Y) made by
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urally occurring mutation (C313Y) in double-muscled
Piedmontese cattle [29] (Figure 2B). The cysteine residue
at the 315-position exists in C-terminal region of the
Mstn peptide (Figures 2B and 5D) and is known to be
one of the important amino acid residues involved in
forming the cysteine knot structure in members of the
TGF-β superfamily [37]. The structure functions as a ho-
modimer to elicit a biological function [39]. Therefore,
we speculate that the structural formation composed of
six essential cysteines in fugu Mstn will be non func-
tional by the truncated form of the peptide resulting
from a point mutation at 317 of Tyr. Eventually, the mu-
tation will be conceivable to cause loss of the Mstn func-
tion in fugu Mstn mutant. The double-muscling
phenotype in medaka and bovine could be similarly ex-
pected for an Mstn-deficient mutant fugu.
Development of HRM analysis
For screening, there are a variety of mutation discovery
technologies such as direct DNA sequencing, CEL I
assay and HRM analysis [13,23,26]. We introduced the
HRM analysis for screening system in fugu because
there is no albino mutant in fugu for specific locus test
(SLT) and the analysis has recently succeeded to detect
point mutations as a screening step for the TILLING ap-
proach [25,26]. But, there was room for improvement
with respect to the cost and variability of output data. In
this study, we have developed a system of HRM analysis
as follows: cost-cutting with fluorescent intercalator;
SYTO 9, introduction of the nested PCR for precision
enhancement and avoidance of variability, speed-up with
384 samples treatment in a single experiment, and high
uniformity of dispensed volume and removal of human
error by using the automatic dispense device. As a result
of the improvement, some mutations could be detected
efficiently in the analysis (Figure 4 and Table 3). It is dif-
ficult for HRM analysis to investigate mutations with a
long amplicon in comparison with the other methods,
but the acquisition of melting profiles in HRM is not
dependent on the location and number of mutations
present in the analyzed fragment. It has been compared
about the mutations detected by the screening ap-
proaches. The results indicate that HRM analysis is use-
ful as resequencing in medaka [26] and more efficient
than CEL I assay in mammals [40]. Taken together, these
demonstrate that HRM analysis is a reliable high-
throughput approach for screening ENU-mutagenized
individuals in potentially various species.
Mutation ratios in fugu TILLING
The mutation ratio in ENU mutagenesis has been calcu-
lated in a SLT using the albino mutant in zebrafish and
medaka [21,41]. The characteristics of the albino mutantin fish reveal mainly red eyes and one of the responsible
genes is tyrosinase. In some aquacultured fish with al-
bino mutants, it may be easy for these ENU-treated fish
to examine the mutation ratio with SLT. However, albino
mutants are not found in nature in all animal species.
Instead of SLT, the mutation ratio was calculated using
base-pairs screened and the number of mutations de-
tected in fugu Mstn gene by HRM analysis (Table 3).
The frequency in fugu (1 mutation per 297 kb) is similar
to the mutation frequency in medaka (1 mutant per
345 kb) and in zebrafish (1 mutant per 235 kb), which
were calculated by resequencing data [13,42]. This sug-
gests that ENU mutagenesis in fugu was efficiently per-
formed in our way and the protocol detailed here will
potentially be useful for constructing a TILLING library.
CG to AT (or reverse) changes are often detected in
HRM analysis, but the endogenous SNPs are also de-
tected as the same changes and give the most significant
difference in this analysis. In our study, there were no
endogenous SNPs in the C-terminal region of the Mstn
gene in both the investigated family of fugu and their
parents (data not shown). Although G > C, C > G, T > A,
A > T mutations were not observed in the 10 mutations
detected in the Mstn gene (Table 3), it was reasonable
results since the appearance frequency of their muta-
tions are also rare in human genome [43].
Generation of an Mstn-deficient mutant in fugu
Our next step will be to generate the Mstn mutant for
the purpose of serving the aquaculture industry. One of
the key components for a successful TILLING project is
a near-perfect ability to recover valuable mutations once
they have been found. For the recovery, TILLING librar-
ies can either be ‘living’ or cryopreserved as suggested
by Moens et al. [22]. A living library is one in which
mutagenized F1 fish are held in pools in tanks while
their fin-tip genomic DNA is screened. A cryopreserved
library is one in which each genomic DNA sample cor-
responds to vials of frozen sperm that can be used in an
in vitro fertilization to generate F2 heterozygotes. As a
large amount of sperm can be stored from a single adult
male of aquacultured fish, in general, the cryopreserved
library is more desirable than ‘living’ library. However,
generation time of many aquacultured fish including
fugu is more than one year, making the construction of
the cryopreserved library time-consuming. We are cur-
rently generating an Mstn-deficient fugu with ‘living’ li-
brary as the next step.
Conclusions
In the present study, the fugu TILLING method was
established from the results in both ENU mutagenesis
and a mutation search technology, HRM analysis. This is
a first report that TILLING is an applicable method for
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might play an important role in producing a fish, which
exhibits a valuable phenotype (e.g., rapid growth, disease
resistance) for the aquaculture industry. We hope that
the TILLING technique will be an alternative to the clas-




Fisheries Research Agency and The University of Tokyo
rule that ethic approval is not necessary for study of fish.
Nevertheless, this project was conducted in accordance
with the Regulation for Animal Experiments in the Fish-
eries Research Agency, which stipulated in the Funda-
mental Guidelines for Proper Conduct of Animal
Experiments and Related Activities in Research Institu-
tions (Ministry of Agriculture, Forestry and Fisheries of
Japan), and under the supervision of the Animal Care
and Use Committee for the National Research Institute
of Aquaculture. In this study, ENU and hormone injec-
tions for fugu were carried out under 0.05% anesthetic
agent (2-phenoxy-ethanol) and hatching fry of fugu were
harvested after they were soaked in sea water containing
ice. All efforts were made to minimize suffering.
Experimental fish and eggs for in vitro fertilization
50 fugu males (body weight: around 1 kg) were pur-
chased from a commercial supplier (Shihou Suisan,
Minami-ise, Mie). The fish were kept at the Nansei sta-
tion of National Research Institute until obtaining sperm
from the ENU-treated fish. Three-year old fugu females
(body weight: around 2–3 kg) were cultivated in 30–50
ton of seawater tanks at the Yashima station of National
Center. Two independent fugu females were used to ob-
tain eggs for in vitro fertilization. Mainly, the fertilization
and harvest of the hatched fry were performed at the
Yashima station. A part of the fertilized-eggs were
packed into seawater without air and sent to Fisheries
Laboratory attached to the University of Tokyo. The fer-
tilized eggs were incubated at 18°C during 8 to 10 days
until harvest of the hatched fry.
Mutagenesis with ENU
All working solutions of ENU (Conc.: 11 mg/ml, Sigma-
Ardrich, St. Louis, MO USA) were freshly prepared fol-
lowing the methods described by Taniguchi et al. [13].
ENU was prepared at three concentrations (7, 70,
120 mg per kg, body weight of fugu). For ENU mutagen-
esis, fugu males (around 1 kg of body weight) were used
and injected into the intraperitoneal with the ENU con-
centrations prepared for 10 mM sodium phosphate buf-
fer (pH 6.3). The injections were repeated 3 times at
weekly intervals to the founder fish. After the last ENUinjection, the fish were injected intramuscularly with hu-
man chorionic gonadotropin (HCG, 500 IU/kg body
weight) or salmon pituitary homogenate (SPH, 10 mg/kg
body weight), consisting of acetone-dried chum salmon
pituitary homogenized in Ringer, was added to HCG be-
cause of increasing the success rate of spermiation in
ENU-treated males. After the hormone treatment, the
sperm was collected from each fish.
Cryopreservation of sperm
The freshly-collected sperm from each fugu male was
suspended at the rate of 1 to 4 in freezing diluents [10%
dimethyl sulphoxide (Sigma-Aldrich Co., Tokyo, Japan)
in 90% fetal bovine serum (Thermo Scientific Co.,
Tokyo, Japan)] and cryopreserved as described by Ohta
et al. [44]. The amount of sperm held in each capillary
(0.5 ml vol.) was enough to fertilize more than twenty
thousand eggs.
In vitro fertilization
About one million unfertilized eggs were squeezed out
from a fugu female, which was induced ovulation by ad-
ministration of an LHRH analogue (des Gly10 [D-Ala6]-
LHRH, 400 μg/kg body weight). Fresh sperm, obtained
from each fugu family line, was used in this method, and
the sperm activity was examined under a light micro-
scope. 0.4 ml of the sperm was added to 12 g of the eggs
(around twenty thousand eggs), and these were mixed
well. After adding seawater to activate the sperm for
fertilization, the eggs were immediately mixed and stood
for 5 minutes. The eggs were washed 3 times with new
seawater to remove the extra sperm after discarding the
remaining seawater. The fertilized eggs were incubated
for 4 to 6 hours at 18°C. The eggs were moved to a
hatching tank with running water and kept at 18°C until
they hatched. At 8 to 10 days after fertilization, around
ten thousand hatched fry were obtained in each family.
These fry were harvested in a 50 ml tube containing
99.5% ethanol (EtOH) and stored at −30°C.
The fertilization ratio was determined at the four-cell
stage with Sera solution (EtOH 6: formalin 3: acetic acid
1), which makes the fertilized eggs transparent. In
addition, one hundred eggs were counted at melano-
phore stage in the fertilized eggs of each cross, and then
incubated at 18°C until hatching. The hatching ratio was
calculated as the number of the hatched fry per 100 fer-
tilized eggs.
Cloning of fugu Mstn gene
RNA was extracted from wild-type fugu skeletal muscle by
RNeasyW Mini Kit (QIAGEN Sciences, MD, USA) accord-
ing to the manufacturer’s instructions. cDNA was synthe-
sized using PowerScript (BD Biosciences Clontech, Palo
Alto, CA, USA). To identify fugu Mstn gene orthologs, we
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search the fugu genome database (http://www.ensembl.
org/Takifugu_rubripes/blastview). Fugu Mstn cDNA se-
quences was amplified using a reverse-transcription PCR
by gene specific primer pairs flanking the ORF: 5′UTR-F1,
5′-TAGAACGCATTTCCACGTCTTC-3′, 3′UTR-R1:
5′-TGGTTTGAGGCCTCTACTCTGG-3′. Amplicons were
cloned into a sequencing vector, and full-length ORF se-
quences were obtained.
Identification of mutations by HRM analysis
Extraction of genomic DNA
In this study, 1,056 hatched fry of fugu were prepared in
each family obtained from in vitro fertilization. A single
fry was placed into each well of 8-well tubes containing
45 μl of 50 mM NaOH, and incubated at 95°C for
10 min. After incubation, 5 μl of 1 M Tris–HCl (pH 8.0)
was added to the lysate immediately for neutralization.
These aliquots were centrifuged at 1,100 × g and room
temperature for 20 min to remove tissue debris. Then,
each 40 μl of supernatant was harvested into 96-deep
well plates and stored at −30°C. Although the genomic
DNA stocks were crude extract and freeze-thawed re-
peatedly, we could use the stocks for our assay during
10 months at least.
Primers
To find the loss-of-function mutations in the fugu Mstn
gene, the third exon of the gene was screened using the
primers designed by Primer3 programs on the web
(source code available at http://bioinfo.ut.ee/primer3-0.4.0/
primer3/). The primer sets and amplicon sizes were as
follows, the forward and reverse primers #1: 5′-CAGC
CATGATCTAACTTCTGCAAG-3′ and 5′-GTTTGAG
GCCTCTACTCTGGTTCT-3′, yielding a fragment of
586 bp; the forward and reverse primers #2: 5′-CTCGCT
CACATGCATTCTGTC -3′ and 5′-CTTGTTCACCAG
GTGGGTGT-3′, yielding a fragment of 268 bp; the
forward and reverse primers #3: 5′-AAGCGCTACAA
GGCCAACTA -3′ and 5′-AAAGCGCTGGAACTGG
TAGA-3′, yielding a fragment of 281 bp. These primers
were used for the 1st-PCR (primer #1), and for the
2nd-PCR (primers #2 and #3) [see PCR].
PCR
PCR amplicons for HRM were obtained by using a
nested-PCR approach. The genomic DNA stocks and all
PCR reaction mixtures were dispensed by a laboratory
automation system, BiomekW3000 (Beckman Coulter,
CA, USA).
The 1st-PCR (PCR1) was performed in 96-well PCR
plates in 15 μl volumes. Reactions included 2 μl of the
genomic DNA solution in 1x KOD-FX PCR buffer
(Toyobo, Tokyo, Japan), with 400 μM of deoxynucleotidetriphosphate, 0.1 U of KOD-FX polymerase (Toyobo),
and 300 nM of each primer. The polymerase was able to
increase precise amplicons with crude samples. The
plates were centrifuged at 200 × g for 1 min and then
PCR was performed in T-Professional Thermocycler
(Biometra, Germany). The cycling conditions were set as
follows: one cycle of 94°C for 2 min, followed by 40 cy-
cles of 98°C for 10 sec; 60°C for 30 sec; 68°C for 40 sec.
The PCR1 products were firstly diluted 10 fold for DNA
sequencing and then finally 140 fold with sterilized
water by using BiomekW 3000. The 140 fold diluted sam-
ples were used as a template for second step of PCR
reactions.
The 2nd-PCR (PCR2) was performed in 384-well PCR
plates (Roche Diagnostics, Basel, Switzerland) in 9 μl
volumes. Reactions included 2 μl of the diluted PCR1
products in 1x Hot-Start Gene Taq PCR buffer (Nippon
Gene, Tokyo, Japan), with 200 μM of deoxynucleotide
triphosphate, 1.25 μM of SYTO 9 (Molecular Probes,
OR, USA) as a fluorescent substance, 0.16 U of Hot-
Start Gene Taq polymerase (Nippon Gene), and 200 nM
of each primer. The plates were centrifuged at 200 × g
for 1 min and then PCR was performed in a 384-well
Light Cycler 480 System (Roche Diagnostics). The cyc-
ling conditions were set as follows: one cycle of 95°C for
5 min, followed by 25 cycles of 95°C for 10 sec; 60°C for
30 sec; 72°C for 20 sec.
Several samples of the PCR1 and PCR2 products were
examined with a microchip electrophoresis system, Mul-
tiNA (Shimadzu, Kyoto, Japan) whether there are the
extra major fragments except for the proper fragment or
not, because non-specific PCR products reduce the per-
formance of HRM assay.
HRM assay
After PCR, the plates were imaged in the 384-well Light
Cycler 480 System (Roche Diagnostics). The PCR prod-
ucts in the plates were heated at 0.1°C/second, and
fluorescence measurements were collected from 65°C to
98°C. Briefly, background-subtracted fluorescence curves
were normalized between 0% and 100%. The curves
were viewed on the subtraction plots to magnify differ-
ences in the shape of the melting curves. The subtrac-
tion plots are useful to cluster the samples into groups.
Clustering of the melting curves for genotype identifica-
tion was carried out using the Light-Cycler software.
A single base-pair change within the probe region
causes a significant shift in melting temperature (Tm) of
the amplicon. In the TILLING method, all the induced
mutations are heterozygous. PCR amplification of het-
erozygotes followed by heat denaturing and annealing
result in the formation of 4 duplexes: two homoduplexes
and two heteroduplexes. Each duplex has a characteristic
melting temperature, and the sum of all transitions can
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samples are identified by differences in shape of the
melting curve.
1,056 of the genomic DNA in each fugu family were
subjected to PCR and two amplicons (268 bp and
281 bp) for screening were examined in HRM. The gen-
omic DNA showing melting curves different from those
of the wild-type allele were selected as mutant candi-
dates. As previously reported in the medaka TILLING
method [26], a substantial number of SNPs might exist
in the fugu genomic DNA used. SNPs were discrimi-
nated from true mutations by defining the same type of
base change detected in more than two sequencing reac-
tions as an SNP. Moreover, the genomic DNA in the
pair of fugu parents extracted from the cut fins was ex-
amined by DNA sequencing to confirm whether it was
the true mutations or not.
Direct sequencing
The positive genomic DNA were screened as candidate
mutations by HRM analysis. The PCR1 products of the
genomic DNA were already diluted 10 fold, and stocked
at −30°C [see PCR]. These samples were used as a tem-
plate for direct DNA sequencing. Sequencing reactions
were carried out using a BigDyeW terminator ver. 3.1 cycle
sequencing kit (Applied Biosystems, CA, USA) and each
forward and reverse primers. PCR cycling condition was
set as follows: one cycle of 96°C for 60 seconds, followed
by 25 cycles of 96°C for 10 seconds; 50°C for 5 seconds;
60°C for 120 seconds. Sequencing products cleaned up
by magnetic bead-based purification system (Agencourt
CleanSEQ, Beckman Coulter) were run on automated
ABI 3130xl DNA analyzers (Applied Biosystems). Se-
quences were analyzed for the presence of heterozygous
mutations using PolyPhred [45] and manual inspection
of the mutated positions. All candidate mutations were
confirmed with new PCR1 products and resequencing
read. The PCR1 products were treated with an ExoSAP-
IT kit (Affymetrix, Ohio, USA) to remove unused
primers and nucleotides.
CEL I assay
To confirm the presence of induced mutations in the
target sequence, CEL I assay was performed with gen-
omic DNA containing the mutations detected by direct
sequencing. CEL I enzyme was purified from celery ac-
cording to Anai et al. [46]. The enzyme activity for each
batch of CEL I was determined experimentally using
control samples.
PCR was performed in 9 μl volumes, and the primer
sets and amplicon size were as follows, the forward and
reverse primers: 5′-CTCGCTCACATGCATTCTGTC-
3′ and 5′-AAAGCGCTGGAACTGGTAGA-3′, yielding
a fragment of 465 bp. Reactions included 2 μl of thediluted PCR1 products in 1x Hot-Start Gene Taq PCR
buffer (Nippon Gene), with 200 μM of deoxynucleotide
triphosphate, 0.16 U of Hot-Start Gene Taq polymerase
(Nippon Gene), and 200 nM of each primer. The cycling
condition was set as follows: one cycle of 95°C for
5 min, followed by 25 cycles of 95°C for 10 sec; 60°C for
30 sec; 72°C for 40 sec.
Directly following the PCR, heteroduplex was formed
by incubating at 98°C for 8 min, 80°C for 20 sec, 70 cy-
cles of 80°C for 7 sec with a decrement of 0.3 sec per
cycle. Next, PCR reactions were incubated with 1 μl CEL
I enzyme solution in a total volume of 10 μl at 37°C for
60 min. CEL I reactions were stopped by adding 10 mM
EDTA. The cleavage products were detected with Mul-
tiNA (Shimadzu).
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